Purnanand Sarma, Immunome CEO

Bet­ting on cell mem­o­ry, Ab­b­Vie pays Im­munome $30M up­front to fur­ther an­ti­body re­search

Ab­b­Vie has tapped Im­munome’s dis­cov­ery plat­form in a heav­i­ly back­end­ed part­ner­ship and op­tion agree­ment in a bid to dis­cov­er 10 an­ti­body-tar­get pairs from three as-yet-un­named tu­mor types.

Ab­b­Vie will pay out $30 mil­lion up­front, but more could be on the way for Im­munome, ac­cord­ing to a joint press re­lease.

As for more mon­ey, Ab­b­Vie could pay out up to $70 mil­lion in plat­form ac­cess pay­ments for Im­munome to con­tin­ue re­search us­ing its hu­man mem­o­ry B cell plat­form, Dis­cov­ery En­gine, as well as $120 mil­lion in de­vel­op­ment and com­mer­cial sale mile­stones for each an­ti­body tar­get “with re­spect to cer­tain prod­ucts de­rived” from the tar­gets that Ab­b­Vie might want to buy – plus sales mile­stones of up to $150 mil­lion per tar­get, which will be based on reach­ing cer­tain lev­els of net sales of prod­ucts, ac­cord­ing to SEC fil­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.